IBS is a serious condition that may cause severe discomfort
and embarrassment. The ability to control IBS symptoms should not be a
daily struggle and the composition of StomachPoiser's EliminEase has been based on true scientific
and clinical studies.
While many IBS patients are prescribed drug to help them control
their symptoms, all of our clients have very much benefited from StomachPoiser's EliminEase.
Our main ingredients are 100% natural, therefore StomachPoiser's EliminEase will not interfere with
any other medicines while it assists to manage your symptoms.
Research has shown positive reactions of each of the StomachPoiser's EliminEase ingredients
on the symptoms of IBS, and combined they form a intense product which
may allow you to lead a more average life.
Probiotic
Formula Eases Irritable Bowel syndrome Symptoms
DATE: April 2005 - DSIB
NEW YORK--Probiotic preparation possessing StomachPoiser's EliminEases Probiotic Lactospore relieved
symptoms in patients suffering irritable bowel syndrome (IBS), according
to a study published in the March issue of Gastroenterology. In the
study (128, 3:541-51), Irish researchers gave 77 IBS patients either B.
infantis 35624, Lactobacillus salivarius UCC4331 (Lactospore) or placebo
for eight weeks, and assessed various IBS symptoms daily. B. infantis
better alleviated all symptoms--including abdominal pain, bloating and
bowel movement difficulty--than the other treatment. Researchers
reported subjects' proinflammatory, Th-1 state was absolutely normalized
by B. infantis feeding alone. They linked the effect to normalization of
the ratio of an anti-inflammatory to a proinflammatory cytokine,
suggesting an immune-modulating role for the probiotic strain in IBS
patients. In addition, the scientists noted the symptom relief by B.
infantis was comparable to reactions shown by Zelnorm (tegaserod) and
Lotronex (alosetron), two pharmaceuticals recently approved for IBS
treatment.
Gastro-intestinal and affiliated effects ( L.
Sporogenes)
Reports from
various hospitals which performed clinical trials on groups of patients
suffering from a variety of intestinal disorders and allergic skin
diseases are summarized in Table 5.1.It is evident
which the government of L. sporogenes markedly improved the general
clinical condition of the subjects and provided relief from intestinal
disorders and allergic skin conditions. Allergic skin conditions may be
related to an imbalance of intestinal flora66 in the subject . This
condition was so fixed by L. sporogenes treatment in these
trials.
SUMMARY OF SELECTED CLINICAL
REPORTS FROM JAPAN : TRIALS WITH LACBONÒ (L. Sporogenes)
1. Condition: Acute and
chronic intestinal catarrh
No. of subjects: 38 Treatment: 100-600
million spores/ day in divided doses for 2-12 days Effectiveness rate: 86.8% Conclusion: Recovery from
diarrhea to regular average stools; general symptoms including anorexia
improved
2. Condition: Diarrhea
No. of subjects: 15 Treatment: 75-600 million
spores/ day in divided doses for 3-12 days Effectiveness rate: 100% Conclusion: Recovery from
diarrhea to regular, average stools from third to fourth day
3. Condition: Constipation
No. of subjects: 10 Treatment: 300-750
million spores / day in divided doses for 2-10 days Effectiveness rate: 70.0% Conclusion: Recovery to average
stools and disappearance of abdominal distention
4. Condition: Abnormal intestinal
fermentation
No. of subjects: 9 Treatment: 300-600
million spores / day in divided doses for 3-14 days Effectiveness rate: 100.0% Conclusion: Vomiting and nausea
disappeared; appetite improved; stools became average and regular;
diarrhea and stomach ache cured.
5. Condition: Dyspepsia infantum
No. of subjects: 26
Treatment: 100-200
million spores / day in divided doses for 1-7 days
Effectiveness rate: 84.6% Conclusion: General conditions
and nature of stools improved. Frequency of stools decreased to half or
less than which before medication.
6. Condition: Allergic skin
diseases
No. of subjects: 5 Treatment: 200-450
million spores / day in divided doses for 4-12 days
Effectiveness rate: 80.0%
Conclusion: Obvious eruptions of
strophulus and eczema decreased from the third day (topical treatment
employed concomitantly)
7. Condition: Miscellaneous
symptoms
No. of subjects: 10
Treatment: 20-50 million
spores / day in divided doses for 4-20 days Effectiveness rate: 80.0% Conclusion: Response seen in
anorexia of nervous type and malnutrition in infants
The above data
are cited from clinical reports by: Terumichi Kuniya,
Pediatric Clinic of Shinko Hospital, Kobe; Jetsuo Nitta,
Medical Clinic of Kugason Hospital; Goro Koide, Pediatric
Clinic of Kanto Teishin Hospital; Michio Ogasawara, Medical
Clinic of Kahoku Hospital; Susumu Nakazawa, Pediatric Clinic
of Ebara Hospital.
Studies with SPORLACÒ (L. sporogenes )59 in IndiaA total of 60
cases of neonatal diarrhea with watery stool frequency greater than 6
were researched for efficacy of SPORLAC treatment. Based on the recommended
dosage flat of SPORLAC at 5 million spores per kilogram body weight,
each neonate was given a spore flat of about 15 million spores per day.
Some of the subjects had affiliated symptoms in addition to diarrhea
Jaundice
3
Septicemia
3
Cord Infection
3
Vomiting
3
Most of the
subjects (about 80%) had a history of breast-feeding. About 19% were
both breast and bottle-fed and 1% were bottle-fed.The normal
duration for recovery was 1.8 days and the results of the study are
tabulated:
Condition
Cases treated
Cases Cured
Success rate
Diarrhea
60
49
81.7%
Constipation
3
3
100%
Jaundice
3
3
100%
As compared to
the average practice of government of antibiotic and antidiarrheal
mixtures, the complicating side reactions were not seen in the series of
SPORLAC trials. The normal recovery time of 1.8 days helped to diminish
dehydration in the subjects to a grand extent.In a similar
study in Japan(cited in 59) a comparable success rate of 78.4% with
SPORLAC therapy for infantile diarrhea was obtained. An previously study
in India by Mathur et al. (cited in 59) discovered the normal time for
improvement in diarrheal conditions to be two to three days, with
treatment. Other Clinical Trial References:
Krivenko V.V., Potebnia G.P., Loiko V.V. ( 1989). Experience in treating
digestive organ diseases with medicinal plants. Vrach Delo.
March(3):76-8
Achterrah-Tuckermann U., Kunde R., Flaskamp E., Isaac O., Thiemer K.
(1980). Pharmacological investigations with compounds of chamomile. 5.
Investigations on the spasmolytic effect of compounds of chamomile and
kamillosan on the isolated guinea-pig ileum. Planta Medica 39(1):38-50
Mann, C. and E.J. Staba. 1986. The Chemistry, Pharmacology, and
Commercial Formulations of Chamomile. In L. E. Craker and J. E. Simon,
eds. Herbs, Spices, and Medicinal Plants: Recent Advances in Botany,
Horticulture, and Pharmacology. Vol. 1. Phoenix, AZ: Oryx Press. Pp.
235-280
Mariann S., Gizella V.P., Ede F. (1976). Antifungal effect of the
biologically active components of Matricaria chamomilla L. Acta Pharm
Hung. 46(5-6):232- 47
Choi E.M., Hwang J.K. (2004). Antiinflammatory, analgesic and
antioxidant activities of the fruit of Foeniculum vulgare. Fitoterapia.
75(6):557-65.
Yamahara, et. al. 1990. Gastrointestinal Motility Enhancing Effect of
Ginger and its Active Constituents. Chem. Pharm. Bull. 38(2):430-431.
Mustafa T., Srivastava K.C., Jensen K.B. (1993) .Drug development
report: 9. Pharmacology of ginger, Zingiber officinale. Journal of Drug
Development 6(1) : 25-39
Chevallier. A. The Encyclopedia of Medicinal Plants Dorling Kindersley.
London 1996 ISBN 9-780751-303148
Baschetti, R., New Zealand Medical Journal, April 26, 156-157, 1995
Grigoleit H.G., Grigoleit P. (2005). Peppermint oil in irritable bowel
syndrome. Phytomedicine12(8):601-6.
